Navigation Links
Vystar® Corporation Receives its Third US Patent and First Chinese Patent for Vytex® Natural Rubber Latex
Date:1/31/2012

ATLANTA, Jan. 31, 2012 /PRNewswire/ -- Vystar Corporation (OTCBB: VYST), the exclusive creator of Vytex® Natural Rubber Latex (NRL), has received its third US and first Chinese patent for its all-natural raw material. The company now has a total of five issued patents in the US and abroad that relate to Vytex NRL, with more than a dozen pending.

(Logo: http://photos.prnewswire.com/prnh/20100203/CL48049LOGO )

The new US patent expands the claims beyond just reducing proteins and recognizes that the process also reduces the level of non-rubber components in Vytex NRL, creating a completely different natural rubber latex. In October 2010, ASTM approved a new category of latex based upon a maximum non-rubber content of 0.5%, which is significantly lower than the maximum of 2.0% allowed in the other categories of latex. Vytex NRL is the first and only commercially available NRL that qualifies for this new category.  Utilizing these criteria, Vytex NRL is cleaner, allowing manufacturers to utilize more cost-effective manufacturing processes and make better end products.  Dipped products use less costly and adverse leaching processes and dyes to produce naturally whiter and more translucent end products such as foams and adhesives. Vytex NRL can save manufacturers time and money in their production lines while also improving thousands of different latex end products such as foams and adhesives.

William R. Doyle, President and CEO of Vystar Corporation said, "Natural rubber latex is a $4.6 billion global market, with little product differentiation. Vytex NRL is really the first fully commercialized, branded latex raw material that offers manufacturers a truly better NRL alternative by saving natural resources in the manufacturing process and in creating distinctively more attractive and desirable end products. These two new patents not only strengthen Vystar's intellectual property rights worldwide, but they are an acknowledgement of the unique attributes of Vytex NRL. This new US patent approval expands protection beyond the process used to make Vytex NRL to the unique end composition of Vytex NRL which leads to the attributes of the end products that can be made only with Vytex NRL."

The recently issued Chinese patent, recognizes the validity of Vystar's second US Patent, which protects the process of producing Vytex NRL, and therefore extends patent protection to China.

Travis Honeycutt, Vystar's founder and technical advisor said, "The Chinese patent is particularly exciting. It demonstrates the importance of Vytex NRL in Southeast Asia and protects our intellectual property rights in that region.  China is one of the leading producers of products made with natural rubber latex and this protection of Vytex NRL's novel process is important for Vystar's growth."

About Vystar Corporation
Based in Duluth, GA, Vystar® Corporation (OTC Bulletin Board: VYST) is the exclusive creator of Vytex Natural Rubber Latex (Vytex NRL), a multi-patented, all-natural, raw material that contains significantly reduced levels of the proteins found in natural rubber latex and can be used in over 40,000 products. Vytex NRL is a 100% renewable resource, environmentally safe, "green" and fully biodegradable. Vystar is working with manufacturers across a broad range of consumer and medical products to bring Vytex NRL to market in adhesives, balloons, surgical and exam gloves, other medical devices and natural rubber latex foam mattresses, pillows and sponges.  For more information, visit www.vytex.com.

Forward-looking Statements: Investors are cautioned that certain statements contained in this document as well as some statements in periodic press releases and some oral statements of VYST officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Forward-looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future VYST actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions made and expectations reflected in the forward-looking statements are reasonable, there is no assurance that the underlying assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and VYST has no specific intention to update these statements.

Investor Contact:
Strategic Universal Advisors, LLC
Stan Altschuler
212-838-1510

Vystar Corporation
Joanne Kearney, Vice President of Marketing
770-965-0383 x 21


'/>"/>
SOURCE Vystar Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vystar® Corporation Spotlights Advantages of Vytex® NRL at the 13th Annual International Latex Conference
2. Vystar® Corporation Appoints Joanne Kearney as Vice President of Marketing
3. Vystar® Corporation Secures a $3M Credit Facility to Fund Growth
4. Kensey Nash Corporation Announces Its Second Quarter Fiscal Year 2012 Earnings Release Date and Teleconference
5. Terumo Americas Holding Acquires Onset Medical Corporation, a Leader in Innovative Sheath Technology Designed for Multiple, Minimally Invasive Clinical Applications
6. School Health Corporation Acquires EnableMart to Expand Product Offering Into Schools
7. CVS Caremark Corporation Settles FTC Deceptive Pricing Charges
8. Volcano Corporation Announces Preliminary Fourth Quarter 2011 Revenues
9. Avista Capital Partners Agrees to Sell BioReliance to Sigma-Aldrich Corporation
10. Kensey Nash Corporation Adopts Cash Dividend Policy; Declares Initial Quarterly Dividend of $0.25 per Share
11. Volcano Corporation Presentation at J.P. Morgan Conference to be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Research and Markets has announced the addition of the ... to 2022" report to their offering. ... financial data derived from varied research sources to present unique ... on the market during the next five years, including a ... markets, regional and country level analysis. The report provides a ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
(Date:6/23/2016)... and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of ... Farma Brasil as the company,s second affiliate in Latin America . ... ... Manager of Astellas Farma Colombia ... ...
Breaking Medicine Technology:
(Date:6/26/2016)... North Carolina (PRWEB) , ... June 26, 2016 , ... ... release of a new product that was developed to enhance the health of felines. ... for centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs ... College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. ... treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
(Date:6/24/2016)... ... , ... A recent article published June 14 on E Online ... on to state that individuals are now more comfortable seeking to undergo not only ... calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
Breaking Medicine News(10 mins):